Analysts have adjusted their price targets for Clarivate, reflecting concerns about potential disruptions from AI and uncertainties surrounding its planned sale of the Life Sciences and Healthcare unit. Despite these challenges, there are indications of strong free cash flow and optimistic growth projections.
Recent evaluations of Clarivate reveal a cautious outlook, with price targets now ranging between $2.40 and $6. Analysts have maintained their ratings but expressed a more conservative view on the company's future performance, primarily due to execution risks and the impact of AI technologies. The highest targets suggest that some analysts still believe in the company’s potential for improvement and execution over time.
On the positive side, the company’s anticipated free cash flow growth of around 10% for FY26 is seen as a stabilizing factor, supporting its valuation even amid reduced price targets. Analysts maintaining Buy ratings suggest that current stock prices may already reflect many known risks, provided management successfully navigates the upcoming portfolio changes.
Conversely, bearish perspectives highlight concerns regarding AI's potential to disrupt traditional business models and the risks associated with the Life Sciences and Healthcare unit sale. These factors have led some analysts to lower their expectations, indicating a more conservative valuation approach. Overall, while there is a mixed sentiment, the ongoing developments and Clarivate's strategic initiatives, including new AI-driven platforms, will be critical in shaping its future trajectory.